Welcome & Introduction

Biomarkers NSCLC

Ceritinib A FRONTier in the 1st Line Treatment of ALK+VE NDCLC

First line Management of ALK Rearranged NSCLC

Slection of 1st Line TKI For EGFR Mutant NSCLC

Targeted treatment for BRAFV600E & MET exon14 mutated NSCLC

Cancer Immunotherapy & role of TECENTRIQ in 2LmNSCLC

IMpower133 Tecentriq plus chemotherapy in 1L extensive stage Small Cell Lung Cancer ES-SCLC

Optimal management of ES-SCLC